Cargando…
Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review
Pancreatic cancer is an extremely malignant tumor with the lowest 5-year survival rate among all tumors. Pancreatic ductal adenocarcinoma (PDAC), as the most common pathological subtype of pancreatic cancer, usually has poor therapeutic results. Immune checkpoint inhibitors (ICIs) can relieve failur...
Autores principales: | Li, Hong-Bo, Yang, Zi-Han, Guo, Qing-Qu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611916/ https://www.ncbi.nlm.nih.gov/pubmed/34819086 http://dx.doi.org/10.1186/s12964-021-00789-w |
Ejemplares similares
-
Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options
por: Kabacaoglu, Derya, et al.
Publicado: (2018) -
The Immune Checkpoint Landscape in Tumor Cells of Pancreatic Ductal Adenocarcinoma
por: Loch, Florian N., et al.
Publicado: (2023) -
Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma
por: Akhuba, Liia, et al.
Publicado: (2023) -
Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects
por: Li, Ke-Yu, et al.
Publicado: (2020) -
Analysis of a novel immune checkpoint, Siglec‐15, in pancreatic ductal adenocarcinoma
por: Chen, Xianlong, et al.
Publicado: (2022)